Dr. Meital Brami joined Pharmaseed’s Preclinical Research & Development Unit in 2016 as a Study director. Later that year, she assumed the role of Head of Preclinical Unit and has been serving as VP of Research & Development since June 2020.
Meital holds a PhD in Biotechnology Engineering and a BSc in Chemical Engineering from the Ben Gurion University (BGU)- Negev. Meital formerly served as an External Lecturer in the Biotechnology Engineering Department of BGU and as a Laboratory Manager in the Sackler Faculty of Medicine at the Tel-Aviv University.
Specializing in various methods exploring the immune system in-vitro and in-vivo, Dr. Brami has published numerous scientific papers, mainly concerning the immunological and glycosylation aspects in ALS disease.
Meital’s motto is “A clever person solves a problem. A wise person avoids it“. In other words, she believes that learning and diligence can help you avoid problems.
Prof. Ronnie Levy joined Pharmaseed in 2010 as Liaison to Pharmaseed’s Scientific Advisory Board and has been serving as Chief Science Officer since 2015.
Prof. Levy holds a PhD and MSc in Chemistry from The Hebrew University, completed a post-doctoral training in pharmacology at the Roche Institute for Molecular Biology and has a full professor nomination at Ben-Gurion University, Beer-Sheva. Ronnie formerly served as the Head of the Radiochemistry Department at the Nuclear Research Center in the Negev (NRCN) and served at the Israel Institute of Biological Research (IIBR) for 30 years, 13 of which as Head of the Pharmacology Department. He also served on the Board of Directors of the Dead Sea Bromine Group as head of the Research Committee. Prof. Levy attended several sabbaticals during which he conducted research at renowned institutes.
Specializing in biopharmaceuticals, preclinical studies, pharmacokinetics, and new drug development, Prof. Levy has published numerous scientific papers and patents, mainly concerning the development of therapeutic agents for treating central nervous system disorders.
Ronnie’s motto is “being old is only in your mind”. In other words, you should always keep a young spirit.
Dr. Lamensdorf, who founded Pharmaseed in 2003, has been responsible for its scientific expansion, national and international collaborations and staff excellence. He was the founder and CEO of PharmaSense in 2001, a biotechnology company that specialized in the treatment of CNS disorders.
Dr. Lamensdorf holds a PhD in Pharmacology from the Faculty of Medicine of the Technion, Israel Institute of Technology, and a BSc and MSc in Clinical Pharmacy from the Hebrew University of Jerusalem Medical School.
He held post-doctoral training programs at the National Institute of Neurological Disorders and Stroke of the National Institute of Health (NIH), Bethesda, Maryland and at the Molecular Genetics Department of Israel’s Weizmann Institute of Science.
Dr. Fabian Arditti joined Pharmaseed’s Preclinical Research & Development Unit in 2013 as a Study Director. In 2015, he joined the Business Development Unit as Director of Immunology & Oncology and in 2017 was promoted to VP of Immunology & Oncology. He also has been serving as Head of Innovation since January 2022.
Fabian holds a PhD in Immunology from Weizmann Institute of Science, a MSc and BSc in Animal Sciences from The Hebrew University and completed a post-doctoral training in Biochemistry at Weizmann Institute of Science and in The Cancer Center of the Hackensack University Medical Center (HUMC) in NJ, USA. Fabian formerly served as head of Hematology Research Laboratory at Kaplan Medical Center, and as R&D Manager at Capsutech (at the NGT incubator).
Specializing in planning of diverse (cell-based, small molecules, antibodies, etc.) therapeutic approaches and novel in-vitro and in-vivo models of disease, Dr. Arditti has published numerous scientific papers, mainly concerning cell therapy for treatment of cancer and organ regeneration, and organ transplantation.
Fabian’s motto is “there are a lot of shades of colors”. In other words, he enjoys all types of music, from classic and opera, through Arabic-oriental, rock, and heavy metal.
Dr. Perri Rozenberg-Hasson joined the Preclinical Research & Development unit of Pharmaseed in 2018 as a Study Director and has served as the Director of the In-Vitro unit since September 2019.
Perri holds a Ph.D. degree in Immunology, a Master’s degree in Cellular Biology, and a Bachelor’s degree in Biology from Tel Aviv University. In her past positions, Perri served as a Teaching Assistant in Immunology, Virology, Microbiology, and Mycology, as well as a Flow Cytometry Analyzer Instructor at Tel Aviv University and a Research assistant at InSight Biopharmaceuticals.
She specializes in various in-vitro assays, primary cell cultures, in-vivo cancer models, and metabolic models. Dr. Rozenberg-Hasson has published numerous scientific papers, mainly concerning the role of eosinophils in cancer, and respiratory and metabolic disorders.